Big data

Big data innovation among pharma companies dropped off in the last quarter

The proportion of pharmaceutical companies hiring for cloud related positions rose to a year-high in August 2021, with 42.7% of the companies included in our analysis recruiting for at least one such position.

An analysis of patent filings shows a decrease in big data related applications in the industry following a rise over the past year.

Powered by 

Research and innovation in big data in the pharmaceutical sector has declined in the last quarter - but remains higher than it was a year ago.

The most recent figures show that the number of big data related patent applications in the industry stood at 49 in the three months ending January - up from 37 over the same period in 2021.

Figures for patent grants related to big data followed a different pattern to filings - shrinking from 24 in the three months ending January 2021 to 15 in the same period in 2022.

The figures are compiled by GlobalData, who track patent filings and grants from official offices around the world. Using textual analysis, as well as official patent classifications, these patents are grouped into key thematic areas, and linked to key companies across various industries.

Big data is one of the key areas tracked by GlobalData. It has been identified as being a key disruptive force facing companies in the coming years, and is one of the areas that companies investing resources in now are expected to reap rewards from.

The figures also provide an insight into the largest innovators in the sector.

F. Hoffmann-La Roche Ltd was the top big data innovator in the pharmaceutical sector in the latest quarter. The company, which has its headquarters in Switzerland, filed 42 big data related patents in the three months ending January. That was up from 15 over the same period in 2021.

It was followed by the United States based Pfizer Inc with 32 big data patent applications, the United States based Johnson & Johnson (15 applications), and Germany based Sartorius AG (12 applications).

F. Hoffmann-La Roche Ltd has recently ramped up R&D in big data. It saw growth of 64.3% in related patent applications in the three months ending January compared to the same period in 2021 - the highest percentage growth out of all companies tracked with more than 10 quarterly patents in the pharmaceutical sector.

Go to article: Home | Tackling insulin prices Go to article: In this issueGo to article: CSafe GlobalGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Molnar-Institute Company Insight Go to article: Molnar-InstituteGo to article: CommentGo to article: Why did the cannabis industry blossom during the pandemic?Go to article: Negative AdCom vote for Amylyx’s ALS drug AMX0035, but hope remainsGo to article: Will Russia’s invasion affect biopharmaceutical licensing agreements?Go to article: Fall from grace? What 2022 may have in stock for biopharmaceutical SPACsGo to article: BEA TechnologiesGo to article: In DepthGo to article: Insulin pricing: could an e-commerce approach cut costs?Go to article: Bacteria and balance: how understanding the vaginal microbiome can help discover new drugs Go to article: Big pharma’s gradual retreat on clinical trials in Russia Go to article: Covid-19, flu combo vaccines an advance but with rollout quandariesGo to article: FDA shows unease about marketing approval applications based on single-country tGo to article: In DataGo to article: How big is the gender pay gap in the pharma industry in Britain?Go to article: Where is trade most likely to be disrupted in pharma from the Russian invasion oGo to article: Big data innovation among pharma companies dropped off in the last quarterGo to article: Event: Outsourcing in Clinical Trials Europe 2022Go to article: EventsGo to article: Next issue